PARPis induce DNA damage in BRCA-mutated tumor cells, resulting in tumor cell death1-3

Image describing how PARPis work.

Source: Zheng et al. Biomed Pharmacother. 2020;123:109661.

PARP repairs SSBs, but in patients with mutated BRCA, use of PARPis will block the repair and cause cancer cells to die1,3 

There are 4 PARPis approved for mCRPC, all of which have different treatment requirements1,4-6

RUBRACA

Can be used as a monotherapy for BRCA-mutated mCRPC before or after chemotherapy and following any ARPI†

olaparib

To be used as a
monotherapy following
enzalutamide 

or abiraterone in 

HRR-mutated mCRPC

To be used in combination
with abiraterone and
either prednisone or prednisolone

 in BRCA-mutated mCRPC

talazoparib

To be used in 
 combination with enzalutamide in 
 HRR-mutated mCRPC

niraparib

To be used as a fixed combination with abiraterone in BRCA-mutated mCRPC, 
 taken in combination 
 with prednisone

Direct clinical comparisons between PARPis cannot be made in the absence of a head-to-head trial.

*Based on in vitro studies.

†Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

RUBRACA is the only PARPi that can be used as a single agent and is not constrained to be used with specific ARPIs1,4-6 

No matter the treatment path, RUBRACA is there when it matters

Earlier identification of genetic mutation status can ensure patients receive timely and targeted treatment with RUBRACA

Below are patient scenarios‡ leading to treatment with RUBRACA.

Photograph of George

GEORGE—AGE 72—DIAGNOSED WITH mCSPC AT AGE 68

ELIGARD
DAROLUTAMIDE
mCRPC
Genetic Testing
RUBRACA

Started on RUBRACA without switching to a different ARPI

Photograph of Frank

FRANK—AGE 66—DIAGNOSED WITH mCSPC AT AGE 64

mCSPC
ELIGARD + ABIRATERONE + DOCETAXEL
mCRPC
Genetic Testing
RUBRACA

Opted for RUBRACA instead of RLT with LuPSMA as next-line therapy

Photograph of Edward

EDWARD—AGE 70—DIAGNOSED WITH LOCALIZED PCa AT AGE 65

ELIGARD
mCRPC
ENZALUTAMIDe
Docetaxel
Genetic Testing
RUBRACA

Started RUBRACA after testing BRCA2+

Photograph of Daniel

DANIEL—AGE 62—DIAGNOSED WITH mCSPC AT AGE 60

Early Genetic Testing
ELIGARD + APALUTAMIDE
mCRPC
RUBRACA
Docetaxel

Already had BRCA2+ status on file, started RUBRACA earlier

‡Not actual patients.
RUBRACA can be used following ANY ARPI and before or after chemotherapy, supporting patients at different points in their mCRPC journey1 

ELIGARD® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.7

ELIGARD may impair fertility in males of reproductive potential.

For Important Safety Information and full Prescribing Information for ELIGARD, visit EligardHCP.com. 

VIEW THE EFFICACY DATA FOR RUBRACA

LEARN MORE

ARPI, androgen receptor-pathway inhibitor; BRCA, BReast CAncer gene; DNA, deoxyribonucleic acid; DSB, double-strand break; HRR, homologous recombination repair; LuPSMA, Lutetium-177-PSMA-617; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; PARPi, poly adenosine diphosphate-ribose polymerase inhibitor; PCa, prostate cancer; RLT, radioligand therapy; SSB, single-strand break. 

REFERENCES: 1. RUBRACA (rucaparib). Prescribing Information. pharmaand GmbH. 2025. 2. Messina C, Cattrini Ci, Soldato D, et al. BRCA mutations in prostate cancer: prognostic and predictive implications. J Oncol. 2020;4986365. 3. Zheng F, Zhang Y, Chen S, et al. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother. 2020;123:109661. 4. Lynparza (olaparib). Prescribing Information. AstraZeneca Pharmaceuticals LP. 2025. 5. Akeega (niraparib and abiraterone acetate). Prescribing Information. Janssen Biotech, Inc. 2024. 6. Talzenna (talazoparib). Prescribing Information. Pfizer Inc. 2025. 7. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2025.

Tap for safety information

 

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

RUBRACA® (rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/
or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.

SELECT IMPORTANT SAFETY INFORMATION

Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur in patients treated with RUBRACA, and are potentially fatal adverse reactions. In 2141 treated patients with ovarian and prostate cancer, MDS/AML occurred in 34 patients (1.6%), including those in long term follow-up. Of these, 14 occurred during treatment or during the 28-day safety follow-up (0.7%).

The duration of RUBRACA treatment prior to the diagnosis of MDS/AML ranged from < 2 months to approximately 72 months. The cases were typical of secondary MDS/
cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/
or other DNA damaging agents.

In ARIEL3, of patients with ovarian cancer associated with a germline and/or somatic BRCA mutation who were treated with RUBRACA, MDS/AML occurred in 9 out of 129 (7%) patients treated with RUBRACA and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.2 to 4.7 years.

In TRITON3, MDS/AML occurred in 2 out of 201 patients (1%) with a BRCA mutation treated with RUBRACA. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.4 to 2.3 years.

Do not start RUBRACA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood counts for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities
(> 4 weeks), interrupt RUBRACA or reduce dose and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after
4 weeks or if MDS/AML is suspected, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.

If MDS/AML is confirmed, discontinue RUBRACA.

Based on findings from genetic toxicity and animal reproduction studies, RUBRACA can cause fetal harm. Advise male patients with female partners of reproductive potential or who are pregnant to use effective methods of contraception during treatment and for 3 months following last dose of RUBRACA. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of RUBRACA.

Most common adverse reactions of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON3 (≥10%, Grade 1-4) were fatigue/asthenia (61%), musculoskeletal pain (53%), nausea (51%), decreased appetite (34%), diarrhea (31%), constipation (31%), vomiting (25%), dyspnea (19%), dysgeusia (18%), edema (18%), abdominal pain (17%), dizziness (16%), weight decreased (16%), rash (13%), headache (12%), peripheral neuropathy (12%), photosensitivity reaction (12%), and urinary tract infection (10%).

Most common select laboratory abnormalities of patients with BRCA-mutated mCRPC treated with RUBRACA
in TRITON3 (≥ 25%, Grade 1-4) were increased ALT (68%), decreased neutrophils
(67%), decreased phosphate (64%), decreased hemoglobin (60%), increased AST (59%), increased creatinine (56%), increased glucose (45%), decreased lymphocytes (43%), decreased sodium (35%), decreased platelets (34%), and increased calcium (29%).

Most common adverse reactions of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), decreased appetite (28%), rash (27%), constipation (27%), vomiting (22%), and diarrhea (20%).

Most common laboratory abnormalities of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON2 (≥ 35%; Grade 1-4) were increased ALT (69%), decreased leukocytes (69%), decreased phosphate (68%), decreased absolute neutrophil count (62%), decreased hemoglobin (59%), increased alkaline phosphatase (44%), increased creatinine (43%), decreased lymphocytes (42%), increased triglycerides (42%), decreased platelets (40%), and decreased sodium (38%).

Concomitant administration of RUBRACA with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates, which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between RUBRACA and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information.

If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.

Full Prescribing Information available at: https://www.rubracahcp.com.

For medical information inquiries within the U.S., contact pharma& at medinfo.us@pharmaand.com.

You may report adverse events to the FDA at 1-800-FDA-1088 or www.fda.gov/
medwatch.

Alternatively, to report an adverse event or reaction, contact pharma& at pv@pharmaand.com.

To report a product complaint, contact pharma& at complaints@pharmaand.com.

Please see full Prescribing Information for RUBRACA.

EXPANDED INDICATION

NOW APPROVED FOR USE 
BEFORE OR AFTER CHEMOTHERAPY

for the treatment of BRCA-mutated mCRPC1

  • ⁨⁨Backed by new clinical data from the Phase 3 trial, TRITON3
  • The first and only PARPi studied head-to-head with chemotherapy2
  • Can be used after ANY ARPI

Learn more about the updated indication in the full Prescribing Information

View Updated Prescribing Information

ARPI, androgen receptor pathway inhibitor; BRCA, BReast CAncer gene; mCRPC, metastatic castration-resistant prostate cancer;

PARPi, poly (adenosine diphosphate-ribose) polymerase inhibitor.

REFERENCES: 1. RUBRACA (rucaparib). Prescribing Information. pharmaand GmbH. 2025. 2. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732.

The information contained in this website is intended for US healthcare professionals only.

By clicking the button below, you acknowledge that you are a US healthcare professional.

I am a US healthcare professional
Cancel

YOU ARE NOW LEAVING RubracaProstateHCP.com

Are you sure you want to leave?

Continue
Cancel and stay
Skip to content
Rubraca® HCP
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.